# UNDERSTANDING THE AESTHETIC IMPACT OF MEDICATION-DRIVEN WEIGHT LOSS

The use of prescription weight loss medications is set to increase globally, with \$100 billion GLP-1 sales forecasted globally by 2030 and will have a considerable impact on the aesthetic market1.

23%

of patients using weight loss medications are already using or considering aesthetic treatments<sup>2</sup>

of patients using weight loss medications get aesthetic treatments following a healthcare professional recommendation<sup>2</sup>

patients to deepen the understanding of this new category.

As the pure-play dermatology category leader, Galderma commissioned new research, surveying

Men and women



Ages



Located in



## THE IMPACT OF MEDICATION-DRIVEN WEIGHT LOSS ON THE FACE

Nearly half (48%) of patients reported significant facial changes due to medication-driven weight loss treatments, with changes typically observed 3-6 months following treatment, and as early as 1-2 months<sup>2</sup>.



Sagging or

loose skin<sup>2</sup>










radiance/glow<sup>2</sup>





"I wanted to get rid of my double chin, but I didn't expect I'd get a turkey neck."

"I noticed that my face felt kind

of longer. The skin was a little

bit looser around my jawline. It felt droopier."

what have I achieved?"

"I didn't feel like myself anymore.

I didn't like to be photographed.

people keep telling me I look tired,

"I wanted to look healthier, so if

I didn't feel good about myself. My self-esteem was low."

## Menopausal women experience:2\*

Facial changes vary across demographics

55-65

Older patients

reported more sagging and loose skin compared

to those under 552

20% vs. 14%

Higher levels of sagging skin

A slimmer face Less radiant skin

39% vs. 30%

15% vs. 11%

\*versus entire patient sample

### ALREADY EXISTING **AESTHETIC AESTHETIC USERS: CONSIDERERS:**

PATIENTS AESTHETICS PERCEPTIONS AND PLANS

HOW THE PHENOMENON IS IMPACTING GLP-1

have undergone treatments to address changes on their face2

plan to undergo aesthetic procedures when they reach their weight loss goal<sup>2</sup>

AN INTEGRATED, HOLISTIC APPROACH IS NEEDED

would have taken additional measures to prevent skin changes if they had known about the effects on the skin prior to starting their

weight loss journey<sup>2</sup>

### **BRIGHTEN** try Sculptra®2 LIFT **ADD VOLUME**

integrates medical and aesthetic professionals counsel to support them in their weight loss journey<sup>2</sup>

of patients show a strong interest in a dual-expertise service that

More than

looking results at three months post follow-up<sup>3</sup>

and have a high likelihood to use Galderma's portfolio of aesthetic solutions to

They seek treatment to

**TIGHTEN** 

address their concerns.

of patients would

try Restylane®2

of patients would

Three-month interim trial data from the latest research commissioned by Galderma demonstrates that the combination of Sculptra® and Restylane Lyft™ or Contour™\* effectively improved the facial aesthetic appearance of patients experiencing

medication-driven weight loss with associated facial volume loss. Three months after their final treatment, patients showed improved mid-face shape and contouring along with improvement in cheek wrinkles and an overall improvement in facial appearance.

Patients reported high satisfaction as early as four weeks after their first treatment session, which was maintained through to three months after their treatment<sup>3</sup>.

balance was improved and said the SHAPE Up Holistic Individualized Treatment (HIT™) enhanced their face's structural harmony\*\* 89% felt more attractive and happier with their appearance, and agreed it provided natural

adverse events reported. \*Restylane Contour is known as Restylane Defyne outside of the US

Safety profile was in line with previous pivotal trial data for all products, with no treatment-related

At Week 4, 85% said their face looked more refreshed, and almost 80% noticed their facial

\*\* SHAPE Up Holistic Individualized Treatment (HIT™) is an individualized treatment approach which enables injectors to leverage their expertise with the renowned Galderma Restylane portfolio to optimize aesthetic outcomes while prioritizing

to support this evolution, through new data and knowledge, in close collaboration with leading healthcare professionals.

With deep skin knowledge, aesthetic expertise and individualized patient-centric treatment approach, Galderma is uniquely positioned

- 1 JP Morgan report. The increase in appetite for obesity drugs. November 2023

patient satisfaction.

Galderma MAC Research. 2024 3 Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects